Glenmark launches fixed-dose triple therapy for COPD
[ad_1] Glenmark Pharmaceuticals on Tuesday said it has launched the world’s first nebulised, fixed-dose triple therapy for the treatment of chronic obstructive pulmonary disease. Nebzmart GFB Smartules and Airz FB Smartules combine three proven medicines – Glycopyrronium, Formoterol, and Budesonide – to reduce airway obstruction, inflammation, and improve lung function and symptom control, the Mumbai-based…